NASDAQ:ABIOArca Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arca Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.20 -3.40 (-26.98 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$9.10Now: $9.20▼$10.2550-Day Range$3.00MA: $4.83▼$19.2152-Week Range$2.21Now: $9.20▼$22.00Volume2.04 million shsAverage Volume4.47 million shsMarket Capitalization$14.63 millionP/E RatioN/ADividend YieldN/ABeta2.96 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic HF. It has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Arca Biopharma. Previous Next 2.2 Community Rank Outperform VotesArca Biopharma has received 122 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArca Biopharma has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentArca Biopharma has received 55.80% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arca Biopharma and other stocks. Vote “Outperform” if you believe ABIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArca Biopharma does not currently pay a dividend.Dividend GrowthArca Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arca Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.97% of the stock of Arca Biopharma is held by insiders.Percentage Held by InstitutionsOnly 12.65% of the stock of Arca Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Arca Biopharma is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arca Biopharma is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArca Biopharma has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABIO Previous Symbol CUSIPN/A CIK907654 Webarcabio.com Phone720-940-2100Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book1.93Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-5,480,000.00 Net MarginsN/A Return on Equity-64.42% Return on Assets-56.56%Miscellaneous Employees15 Outstanding Shares1,590,000Market Cap$14.63 million Next Earnings Date8/6/2020 (Estimated) OptionableNot Optionable NASDAQ:ABIO Rates by TradingView Receive ABIO News and Ratings via Email Sign-up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter. Arca Biopharma (NASDAQ:ABIO) Frequently Asked Questions How has Arca Biopharma's stock been impacted by COVID-19 (Coronavirus)? Arca Biopharma's stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABIO stock has increased by 173.8% and is now trading at $9.20. View which stocks have been most impacted by Coronavirus. When is Arca Biopharma's next earnings date? Arca Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Arca Biopharma. How were Arca Biopharma's earnings last quarter? Arca Biopharma Inc (NASDAQ:ABIO) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $1.21. View Arca Biopharma's earnings history. Has Arca Biopharma been receiving favorable news coverage? Media headlines about ABIO stock have trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arca Biopharma earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutArca Biopharma. Who are some of Arca Biopharma's key competitors? Some companies that are related to Arca Biopharma include Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Trinity Biotech (TRIB), GeneNews (GNWSF), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ). View all competitors. What other stocks do shareholders of Arca Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arca Biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Eyegate Pharmaceuticals (EYEG), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), AVEO Pharmaceuticals (AVEO) and Cidara Therapeutics (CDTX). Who are Arca Biopharma's key executives? Arca Biopharma's management team includes the following people: Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 74)Mr. Thomas A. Keuer, Chief Operating Officer (Age 60)Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 60)Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 57) What is Arca Biopharma's stock symbol? Arca Biopharma trades on the NASDAQ under the ticker symbol "ABIO." Who are Arca Biopharma's major shareholders? Arca Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (1.79%). View institutional ownership trends for Arca Biopharma. Which institutional investors are buying Arca Biopharma stock? ABIO stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View insider buying and selling activity for Arca Biopharma. How do I buy shares of Arca Biopharma? Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arca Biopharma's stock price today? One share of ABIO stock can currently be purchased for approximately $9.20. How big of a company is Arca Biopharma? Arca Biopharma has a market capitalization of $14.63 million. Arca Biopharma employs 15 workers across the globe. What is Arca Biopharma's official website? The official website for Arca Biopharma is arcabio.com. How can I contact Arca Biopharma? Arca Biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2100 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
